Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMXGQYZ)

• Drug Name: Fleroxacin Drug Info
• Synonyms: FLRX; Fleroxacine; Fleroxacino; Fleroxacinum; Fleroxicin; Megalocin; Megalone; Megalosin; Quinodis; Fleroxacine [French]; Fleroxacino [Spanish]; Fleroxacinum [Latin]; AM 833; F0646; AM-833; Megalocin (TN); Megalone (TN); Quinodis (TN); Ro 23-6240; Ro-236240; Ro 23-6240/000; Fleroxacin (JAN/USAN/INN); Fleroxacin [USAN:BAN:INN:JAN]; Ro-23-6240/000; 6,8-Difluoro-1-(2-fluoroethyl)-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 6,8-Difluoro-1-(2-fluoroethyl)-1,4-dihydro-7-(4-methylpiperazino)-4-oxo-3-quinolinecarboxylic acid; 6,8-Difluoro-1-(2-fluoroethyl)1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 6,8-difluoro-1-(2-fluoroethyl)-7-(4-methyl-1-piperazinyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid; 6,8-difluoro-1-(2-fluoroethyl)-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid

Indication

Disease Entry	ICD 11	Status	REF
Bacterial infection	1A00-1C4Z	Approved	[1]

• Therapeutic Class: Antiinfective Agents
• Cross-matching ID:
  PubChem CID: 3357
  ChEBI ID: CHEBI:31810
  CAS Number: CAS 79660-72-3
  TTD Drug ID: DMXGQYZ

Molecule-Related Drug Atlas

Drug(s) Targeting DNA topoisomerase II (TOP2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[4]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[5]
Teniposide	DMLW57T	Acute lymphoblastic leukaemia	2A85	Approved	[4]
Mitoxantrone	DMM39BF	Acute myelogenous leukaemia	2A41	Approved	[6]
Idarubicin	DMM0XGL	Acute myelogenous leukaemia	2A41	Approved	[4]
Epirubicin	DMPDW6T	Solid tumour/cancer	2A00-2F9Z	Approved	[4]
Lomefloxacin	DMVRH9C	Bacterial infection	1A00-1C4Z	Approved	[7]
Dexrazoxane	DMD7X1O	Breast cancer	2C60-2C65	Approved	[4]
Podofilox	DMT2EJP	Condyloma	1A95	Approved	[8]
Enoxacin	DMYTE6L	Acute gonococcal cervicitis		Approved	[9]

Drug(s) Affected By Potassium voltage-gated channel subfamily H member 2 (KCNH2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metoclopramide	DMFA5MY	Nausea	MD90	Approved	[10]
Quinidine	DMLPICK	N. A.	N. A.	Approved	[11]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[12]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[13]
Clarithromycin	DM4M1SG	Acute maxillary sinusitis		Approved	[13]
Disopyramide	DM5SYZP	Long QT syndrome	BC65.0	Approved	[14]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[15]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[16]
Dofetilide	DMPN1TW	Sinus rhythm disorder	BC9Y	Approved	[17]
Flecainide	DMSQDLE	Tachyarrhythmias	BC71	Approved	[13]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
DNA topoisomerase II (TOP2)	TT0IHXV	TOP2A_HUMAN; TOP2B_HUMAN	Inhibitor	[2]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Potassium voltage-gated channel subfamily H member 2 (KCNH2)	OTZX881H	KCNH2_HUMAN	Protein Interaction/Cellular Processes	[3]

References

• [1] Drug information of Fleroxacin, Health Canada, 2007.
• [2] Fleroxacin overview. Chemotherapy. 1996 Mar;42 Suppl 1:1-9.
• [3] Computational and experimental studies on the inhibitory mechanism of hydroxychloroquine on hERG. Toxicology. 2021 Jun 30;458:152822. doi: 10.1016/j.tox.2021.152822. Epub 2021 May 28.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [5] Etoposide, topoisomerase II and cancer.Curr Med Chem Anticancer Agents.2005 Jul;5(4):363-72.
• [6] Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol. 1998 Jan;100(1):142-6.
• [7] Inhibition of human topoisomerase IIalpha by fluoroquinolones and ultraviolet A irradiation. Toxicol Sci. 2002 Sep;69(1):16-22.
• [8] Antitumor properties of podophyllotoxin and related compounds. Curr Pharm Des. 2000 Dec;6(18):1811-39.
• [9] Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin Pharmacokinet. 1988 Feb;14(2):96-121.
• [10] Comparison of the effects of metoclopramide and domperidone on HERG channels. Pharmacology. 2005 Apr;74(1):31-6. doi: 10.1159/000083234. Epub 2005 Jan 7.
• [11] Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol. 2005 Jan;16(1):54-8. doi: 10.1046/j.1540-8167.2005.04470.x.
• [12] Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds. Assay Drug Dev Technol. 2004 Oct;2(5):497-506. doi: 10.1089/adt.2004.2.497.
• [13] Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. Toxicol Sci. 2013 Dec;136(2):581-94. doi: 10.1093/toxsci/kft205. Epub 2013 Sep 19.
• [14] Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs. Br J Pharmacol. 2008 Nov;155(6):957-66. doi: 10.1038/bjp.2008.325. Epub 2008 Aug 25.
• [15] Comparison of HERG channel blocking effects of various beta-blockers-- implication for clinical strategy. Br J Pharmacol. 2006 Mar;147(6):642-52. doi: 10.1038/sj.bjp.0706508.
• [16] Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels. Naunyn Schmiedebergs Arch Pharmacol. 1999 Mar;359(3):212-9. doi: 10.1007/pl00005344.
• [17] Redox state dependency of HERGS631C channel pharmacology: relation to C-type inactivation. FEBS Lett. 2000 May 26;474(1):111-5. doi: 10.1016/s0014-5793(00)01586-6.